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The cause(s) of amyotrophic lateral sclerosis (ALS) is not fully understood in the vast majority of cases and the mechanisms involved in motor
neuron degeneration are multi-factorial and complex. There is substantial evidence to support the hypothesis that oxidative stress is one
mechanism by which motor neuron death occurs. This theory becomes more persuasive with the discovery that mutation of the anti-oxidant
enzyme, superoxide dismutase 1 (SOD1), causes disease in a significant minority of cases. However, the precise mechanism(s) by which mutant
SOD1 leads to motor neuron degeneration have not been defined with certainty, and trials of anti-oxidant therapies have been disappointing. Here,
we review the evidence implicating oxidative stress in ALS pathogenesis, discuss how oxidative stress may affect and be affected by other
proposed mechanisms of neurodegeneration, and review the trials of various anti-oxidants as potential therapies for ALS.
© 2006 Elsevier B.V. All rights reserved.Keywords: Amyotrophic lateral sclerosis; Oxidative stress; Superoxide dismutase; Anti-oxidant; Clinical trials; Therapy1. Introduction
Amyotrophic lateral sclerosis (ALS), or motor neuron
disease (MND) as it is often called, is one of the more prevalent
adult-onset neurodegenerative diseases, with an incidence of 1–
2/100,000 in most populations. The disease is characterised by
progressive injury and death of lower motor neurons in the
spinal cord and brainstem, and upper motor neurons in the
motor cortex. Disease progression is usually rapid, and the
average survival is only 2–3 years from symptom onset. Despite
extensive research, the cause of disease is unknown in the
majority of cases, and the mechanisms of motor neuron injury
are complex and incompletely understood. The discovery that
approximately 20% of familial MND cases (5–10% of all cases
are familial) are caused by mutations in copper/zinc superoxide
dismutase (Cu/Zn SOD, SOD1) [1] has enabled development of
animal and cell culture models, from which much of our
understanding of the mechanisms of neurodegeneration in ALS
has come. This work has highlighted several major mechan-⁎ Corresponding author. Tel.: +44 0114 2713579; fax: +44 0114 2261201.
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doi:10.1016/j.bbadis.2006.03.008isms, which are not mutually exclusive. These include:
oxidative stress; excitotoxicity caused by aberrant glutamate
signalling; mitochondrial dysfunction; disruption of the neuro-
filament network and intracellular trafficking along neurofila-
ments; aggregation of proteins; and involvement of non-
neuronal cells in the vicinity of motor neurons. One or more
of these mechanisms culminate in the death of motor neurons by
what is now thought to include a caspase-dependent
programmed cell death pathway resembling apoptosis [2].
Here, we review the evidence for oxidative stress as a
mechanism of neurodegeneration in ALS, describe how it
may interact with other proposed mechanisms of neurodegen-
eration, and consider whether anti-oxidants should be pursued
as a promising group of neuroprotective compounds.
2. Sources of oxidative stress
Reactive oxygen species (ROS) arise as by-products of
aerobic metabolism [3–5]. For a comprehensive review of
reactive oxygen species, we refer the reader to Halliwell and
Gutteridge [5]. Most cellular ROS arise due to “leakage” of
electrons from the mitochondrial respiratory chain resulting in
Fig. 2. Sources of reactive oxygen species and their targets. ROS are produced
during oxidative phosphorylation in mitochondria, by oxidative enzymes
including cytochrome P450 in the endoplasmic reticulum, and by xanthine
oxidase (XO) and reduced metal ions in the cytosol. Cellular targets attacked by
ROS include DNA, proteins, membrane lipids, and mitochondria.
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phosphorylation to produce hydrogen peroxide (H2O2) and the
superoxide radical anion (O2
−U, Fig. 1). Whilst cytochrome C
(the terminal oxidase of the electron transport chain, and the
only one that uses molecular oxygen) has a high affinity for
oxygen and there is no evidence that it releases oxygen radicals
[5], earlier components of the electron transport chain (notably
complexes I and III) do leak some electrons to molecular
oxygen [6]. It has been estimated that at physiological levels of
O2, 1–3% of molecular oxygen reduced in mitochondria may
form superoxide [5]. Since approximately 85–90% of oxygen is
used by mitochondria, this makes the mitochondrion the major
site of ROS production. The remaining 10–15% of oxygen is
used by other cellular oxidative enzymes, including xanthine
oxidase in the cytoplasm and the oxidase activity of the
cytochrome P450 system in the endoplasmic reticulum, which
can also yield ROS (Figs. 1 and 2) [5].
Whilst superoxide itself is not highly reactive [7], it will react
quickly with the nitric oxide radical (NO.), produced by nitric
oxide synthase, to form the potent oxidant, peroxynitrite
(ONOO−, Fig. 1) [8,9]. Similarly, hydrogen peroxide is a
weak oxidising agent and is generally poorly reactive, but
slowly decomposes to form the highly reactive hydroxyl
radical, .OH [5]. This can be accelerated in the presence of
reduced metal ions, such as ferrous ion, Fe2+ (Fenton reaction,
Fig. 1). Both peroxynitrite and hydroxyl radicals are highly
reactive and can cause oxidative damage to proteins, lipids and
DNA. Such damage can alter protein conformations and disrupt
enzyme active sites, change the properties of cellular mem-
branes by oxidation of unsaturated fatty acids, and introduce
mutations into DNA (Fig. 2). Some components of the electron
transport chain are encoded by mitochondrial DNA, which has a
10-fold higher mutation rate than nuclear DNA [10]. The
mutation rate of mitochondrial DNA increases further with age,
suggesting that the oxidative environment in which it resides
contributes to this increased mutation rate, and this vicious
cycle of ROS production and decreased mitochondrial efficien-
cy is considered to be a major cause of aging [11–13].
3. Anti-oxidant defence mechanisms
The cell combats this continuous production of harmful ROS
with a multi-faceted anti-oxidant defence mechanism. TheseFig. 1. Production of reactive oxygen species. Incomplete reduction of molecular
oxygen during oxidative phosphorylation and other oxidative reactions leads to
production of superoxide radicals (O2
−U) and hydrogen peroxide (H2O2).
Reaction between superoxide and nitric oxide (NO) produces peroxynitrite
(ONOO−). Hydrogen peroxide is converted to hydroxyl radical (.OH) by
cytosolic transition metal cations in the Fenton reaction. ROS are shown in red.
(For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)defences include: (1) catalytic removal of reactive species by
enzymes such as superoxide dismutase, catalase, and peroxi-
dase; (2) scavenging of reactive species by low molecular
weight agents either synthesised in vivo (including glutathione,
α-keto acids, lipoic acid and coenzyme Q) or obtained from the
diet (including ascorbate (vitamin C) and α-tocopherol (vitamin
E)); (3) minimising the availability of pro-oxidants such as
transition metals; and (4) protection of bio-molecules by heat-
shock proteins which act to either remove or facilitate repair of
damaged proteins [5]. Superoxide dismutase (SOD) enzymes
catalyse the removal of superoxide radicals in a dismutation
reaction where one superoxide radical is oxidised and another is
reduced (Fig. 3A) [14]. Two unrelated SOD enzymes are
present within eukaryotic cells; copper/zinc SOD (Cu/Zn SOD,
SOD1) in the cytosol and mitochondrial intermembrane space,
and manganese SOD (Mn SOD, SOD2) in the mitochondrial
matrix [14,15]. Many eukaryotes also have an extracellular Cu/
Zn SOD [16]. That unrelated SOD enzymes have evolved
highlights the importance of anti-oxidant defence. The
hydrogen peroxide that is produced can be degraded to water
and oxygen by catalase (Fig. 3B.I), or can be metabolised by
peroxidase enzymes, such as the glutathione peroxidases, which
use reduced glutathione as a co-factor that is oxidised by
hydrogen peroxide (Fig. 3B.II) [17]. The oxidised glutathione is
recycled to its reduced form by glutathione reductase enzymes,
thereby maintaining a high ratio of reduced/oxidised glutathi-
one. Ascorbate acts as an anti-oxidant by donating one electron
to a reactive radical to produce the much less reactive ascorbyl
radical (Fig. 3C). Ascorbyl is poorly reactive, but undergoes a
dismutation reaction where one ascorbyl radical donates an
electron to another, with the result of regenerating one ascorbate
and one molecule of dehydroascorbate, which is rapidly
degraded [18]. Alpha-tocopherols react with lipid peroxyl
radicals more rapidly than these radicals can react with adjacent
fatty acids or membrane proteins, and therefore terminate the
chain reaction of lipid peroxidation (Fig. 3D). The α-tocopherol
radical produced can be recycled by reaction with ascorbate, or
Fig. 3. Anti-oxidant mechanisms. (A) Superoxide dismutase oxidises one su-
peroxide radical and reduces another, to produce hydrogen peroxide and oxygen.
(B) Hydrogen peroxide can be degraded by catalase, glutathione peroxidases
and, in mitochondria, by peroxiredoxin 3. Glutathione and peroxiredoxin 3 are
recycled by glutathione reductase and thioredoxin, respectively. (C, D) Low
molecular weight agents such as ascorbate and α-tocopherol can react with and
remove various ROS. Ascorbyl radical is poorly reactive and is degraded to
produce oxalic and L-threonic acids, as well as regenerating some ascorbate [5].
Alpha-tocopherol radical can be recycled by reaction with ascorbate, or can be
further metabolised and excreted.
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such as transferrin and albumin in extracellular fluids sequester
transition metal ions thereby preventing them from catalysing
generation of hydroxyl radicals [19].
3.1. Mitochondrial anti-oxidant defence mechanisms
As the major site of ROS generation, it is not surprising
that the mitochondrion has its own anti-oxidant defence
mechanisms. Superoxide dismutase again plays a major role in
anti-oxidant defence, but although SOD1 is found in the
intermembrane space [15,20,21] where it can remove superox-
ide generated at the outer face of the inner mitochondrial
membrane [22], it is SOD2, present in the mitochondrial matrix,
that is the major mitochondrial SOD enzyme [23,24]. Since
superoxide does not readily cross cell membranes, SOD2 has a
vital role in anti-oxidant defence in mitochondria, evident in that
SOD2 knock-out mice develop mitochondrial deficiencies
associated with ROS toxicity and die in early postnatal life
[25,26]. Catalase is not present within mitochondria, so the
hydrogen peroxide produced by SOD2 is degraded by
glutathione peroxidases [27,28] or peroxiredoxin 3 (Prx3)
[29,30] within the mitochondrial matrix. Prx3 homodimers
catalyse removal of hydrogen peroxide in a mechanism
reminiscent of glutathione peroxidase; hydrogen peroxide
oxidises the thiol group on an N-terminal conserved cysteineresidue in one Prx3 subunit, which in turn reacts with a second
conserved thiol group at the C-terminal of the other Prx subunit
(Fig. 3B.III). The oxidised Prx3 is then recycled by reaction with
thioredoxin (Trx), which is itself recycled to its reduced form by
thioredoxin reductase. Whilst the peroxidase activity of Prx3 is
low compared to that of catalase and the glutathione peroxidases
[29], it is more abundant within mitochondria [31], and is up-
regulated in response to oxidative stress [32], making it an
important factor in mitochondrial anti-oxidant defence.
4. Evidence for oxidative damage in ALS
Numerous studies have found evidence of increased
oxidative stress in ALS pathogenesis. Extensive evidence
shows increased oxidative damage to protein in ALS post
mortem tissue compared to control samples. Protein carbonyl
levels have been found to be elevated in both spinal cord [33]
and motor cortex [34] from sporadic ALS cases, and increased
3-nitrotyrosine levels, a marker for oxidative damage mediated
by peroxynitrite, was observed in both sporadic and SOD1
familial ALS patients [35–37]. Immunoreactivity to 3-nitrotyr-
osine was most prominent within large ventral horn neurons.
Markers for protein and lipid oxidation were localised in motor
neurons, reactive astrocytes and microglia/macrophages in the
grey matter neuropil of sporadic ALS patients that were absent
in control spinal cords [38]. Oxidative damage to DNA,
measured by levels of 8-hydroxy-2′-deoxyguanosine (8-
OHdG), has also been found to be elevated in whole cervical
spinal cord from ALS patients [39] and to be most prominent
within the ventral horn [34]. Increased levels of 8-OHdG
[40,41], 4-hydroxynonenal (indicative of lipid peroxidation)
[42,43], and ascorbate free radical [41] have been reported in
cerebrospinal fluid (CSF) samples from ALS patients. Elevated
3-nitrotyrosine levels [44] and nitrated manganese superoxide
dismutase [45] have also been measured in CSF samples from
ALS patients, although a more recent study found 3-
nitrotyrosine was elevated in CSF from only a minority of
ALS patients, and was not significantly different to control
individuals [46].
Whether oxidative stress is a primary cause of pathogenesis
in ALS, or is merely a consequence of the disease has long been
debated. The discovery that approximately one fifth of familial
ALS cases showed genetic linkage to the SOD1 locus [1] was
therefore exciting, given the major role that SOD1 has in anti-
oxidant defence. This finding placed oxidative stress as a central
mechanism in familial ALS pathogenesis. Transgenic mouse
models of ALS expressing mutant human SOD1 support the
human studies showing increased oxidative damage to protein,
lipid and DNA [47–52]. Indeed, one of the most severely
oxidised proteins in the G93A-SOD1 transgenic mouse was
found to be mutant SOD1 itself [48]. It was initially suggested
that mutations in SOD1 may be toxic through either: (1) loss of
function leading to increased levels of superoxide, which can
react with nitric oxide to produce peroxynitrite [53,54]; (2) a
dominant-negative mechanism whereby the mutant SOD1
protein is not only inactive, but also inhibits the function of
normal SOD1 expressed by the normal allele [1]; or 3) increased
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and hydroxyl radical [1]. However, subsequent investigation
found that the mechanism through which mutant SOD1 causes
disease is more elusive.
5. SOD1 chemistry
Cu/Zn superoxide dismutase (SOD1, EC 1.15.1.1) is a small,
ubiquitous, homodimeric protein found in the cytosol that forms
a major component of the anti-oxidant response. SOD1 uses the
copper ion in its active site to catalyse a two-step redox reaction
that dismutates superoxide radicals to oxygen and hydrogen
peroxide (Fig. 4A) [14]. Access to the active site, where the
copper ion resides along with a zinc ion, is restricted.
Superoxide anions are guided through a narrow channel to the
small active site by highly conserved positively charged
residues lining the channel [55]. This conformation encourages
superoxide entry, but excludes molecules of larger size, thereby
protecting the metal cations from participating in undesirable
side reactions. Within the active site, the dismutation reaction
occurs rapidly [56]. The uncharged hydrogen peroxide is free toFig. 4. SOD1 chemistry. (A) Superoxide dismutation reaction. (B) Peroxidase
activity of SOD1, producing superoxide radical, hydroxyl radical, and (if
performed in isolation) can irreversibly inactivate SOD1. Im, imidazole ring.
(C) Elevated superoxide levels, caused by reduced SOD1 activity, lead to
increased peroxynitrite production, that reacts with SOD1 leading to tyrosine
nitration. (D) Zinc-deficient SOD1 is reduced by cellular reducing agents such
as ascorbate, so it can then catalyse the reverse of the dismutase reaction to
produce superoxide, which in turn reacts with nitric oxide to produce
peroxynitrite. Cellular reductants ensure recycling of SOD1, enabling further
superoxide generation.leave the active site, and is subsequently converted to oxygen
and water by catalase or glutathione peroxidase.
Howover one hundred differentmutations in the 153 amino acid
SOD1 sequence can lead to selective motor neuron death remains
controversial. Initial hypotheses suggested that ALS-causing
mutations in SOD1 altered the protein conformation to give a
mis-folded or unstable enzyme with reduced dismutase activity
thereby leading to increased oxidative stress [53]. Early experi-
mental evidence supported this hypothesis with two independent
studies reporting SOD1 activity in red blood cell lysates from fALS
patients to be less than half the activity from controls [54,57], and a
further report describing reduced SOD1 activity in fALS cortical
tissue [58]. However, it soon became apparent that a simple loss of
function could not explain mutant SOD1 toxicity, since the level of
dismutase activity was found to vary between different fALS-
linked SOD1mutations [59], with some, such as the G37Rmutant,
retaining full dismutase activity [60]. No fALS cases have been
found with mutations that lead to a total loss of SOD1. Data from
SOD1 transgenic mouse models also invalidate the loss of
dismutase function hypothesis: (1) SOD1 mutations that do not
decrease dismutase activity are sufficient to cause motor neuron
degeneration [61–64]; (2) increasing or decreasing levels of wild-
type SOD1 had no effect on mutant SOD1-related ALS [65]; and
(3) a SOD1 knock-out mouse did not develop ALS [66]. If mutant
SOD1 does not cause fALS through loss of dismutase activity, it
appears that mutant SOD1 gains an additional toxic function.
Since many of the mutations identified in SOD1 alter
residues important in β-barrel formation and dimer contact
rather than at the active site [54], it has been proposed that ALS-
causing mutations in SOD1 may lead to a more open
conformation, allowing aberrant substrates to enter the active
site and react with the copper and/or zinc ions sequestered
within. Two hypotheses have been proposed for this new toxic
function. Mutant SOD1 could act as a peroxidase in the reverse
of its normal reaction, or could react with peroxynitrite to cause
tyrosine nitration (Fig. 4B–D).
In addition to its dismutase activity, SOD1 can also act as a
peroxidase by using the hydrogen peroxide produced in the
conventional dismutase reaction as a substrate. In this way, SOD1
can catalyse the reverse reaction of the dismutation, and the reduced
copper ion can then use more hydrogen peroxide to produce
hydroxyl radicals through the Fenton reaction (Fig. 4B) [67–69].
When this reaction occurs in isolation, the SOD1 rapidly becomes
inactivated because the bound hydroxyl radical attacks and oxidises
the imidazole ring on the adjacent histidine residue to which the
copper ion is bound [67]. However, other small electron donors,
such as formate, glutamate and urate, are able to pass through the
positively charged channel to the active site where they can
compete with the imidazole ring to scavenge the highly reactive
hydroxyl radicals, so that the peroxidase activity of SOD1 can
continue [67,69]. Such free-radical generation by SOD1 has been
implicated in ALS; the G93A-SOD1 mutation retains dismutase
activity equivalent to wild-type SOD1 [61], but has a greater free
radical generating activity [70].
Mutations in SOD1 may result in increased peroxynitrite
levels through two hypothesised mechanisms. The first
hypothesis assumes that the mutant SOD1 activity is lower
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equilibrium towards higher superoxide concentrations. Since
superoxide reacts with nitric oxide more rapidly than it does
with native SOD1, there would be a concomitant increase in
peroxynitrite levels, which in turn reacts with SOD1 to form a
nitronium-like intermediate that nitrates tyrosine residues on
cellular proteins (Fig. 4C) [53]. Although increased nitro-
tyrosine levels have been reported in SOD1-ALS patients
[37,44] and mutant SOD1 transgenic mice [47,52], it is now
understood that many SOD1 mutants retain dismutase activity
[59,60,71] so this mechanism could only occur in mutants
where dismutase activity is reduced.
The second hypothesis is based on the finding that several
ALS-linked SOD1 mutations, including A4V and I113T, show
a reduced affinity for zinc [72,73]. When replete with both
copper and zinc, neither wild-type nor four ALS-SOD1
mutants were found to be toxic to cultured motor neurons, but
when they were made zinc-deficient (Zn(−)SOD1), all
induced apoptosis in motor neuron cultures [74]. Removal
of copper protected neurons from Zn(−)SOD1, suggesting the
normal dismutase activity of SOD1 contributes to toxicity.
The altered geometry associated with Zn(−)SOD1 enabled
reductants other than superoxide, including ascorbate, gluta-
thione and urate, to enter the active site and react rapidly with
oxidised Cu2+ [74]. The now-reduced Cu+ is able to catalyse
the reverse of its usual dismutase reaction, using oxygen to
generate superoxide, which in turn reacts with freely diffusing
nitric oxide to produce peroxynitrite and cause tyrosine
nitration as described previously [53] (Fig. 4D). Therefore, Zn
(−)SOD can continue to produce superoxide at the expense of
cellular anti-oxidants [74]. If the superoxide produced in this
way is not released from Zn(−)SOD1, but reacts with nitric
oxide to produce peroxynitrite, it would explain why an
excess of wild-type SOD1 cannot compensate for this
aberrant redox activity [65]. It is interesting that A4V, a
mutant associated with rapid disease progression [75], showed
the lowest zinc affinity of mutants studied [73].
The importance of peroxynitrite synthesis in mutant SOD1
toxicity remains controversial. If such a mechanism was
central to the toxic gain of function, it would be hypothesised
that reduction of nitric oxide levels by inhibition of neuronal
NO synthase would reduce mutant SOD1 toxicity to motor
neurons. Although this was found in one study using cultured
motor neurons [74], inhibition of neuronal NO synthase had
no effect on survival of mutant SOD1 transgenic mice
[76,77]. Similarly, if increased peroxynitrite was a major
mechanism leading to neurodegeneration, increased levels of
tyrosine nitration would be expected. Elevated levels of free
3-nitrotyrosine have been found in G37R- and G93A-SOD1
transgenic mice compared to mice expressing human wild-
type SOD1 [47,78], and also in both sporadic and SOD1-ALS
patients [37]. However, levels of protein-bound nitro-tyrosine
were unchanged at all ages in G37R- and G85R-SOD1 mice,
and also in end-stage of sporadic or mutant SOD1-mediated
human ALS [78].
All of the proposed mechanisms for the mutant SOD1 gain
of toxic function require a copper ion to be present within theactive site. In support of this, neither loss of dismutase activity
nor reduced copper binding is a common property shared by
ALS-associated SOD1 mutants [59,71]. However, deletion of
the copper chaperone for SOD1 (CCS), which led to a reduction
in copper loading into SOD1 of at least 90% and a marked
reduction of SOD1 activity, had no effect on disease onset,
progression or pathology of G93A, G37R or G85R mutant mice
[79]. Similarly, mutation of the four histidine residues that hold
the copper ion in the active site (including the two disease-
causing mutations, H46R and H48Q) abolished the copper
binding site and produced a completely inactive protein, but still
caused a motor neuron disease in a transgenic mouse that was
clinically and pathologically similar to other mouse models of
ALS [80]. These studies showing that enzymatically inactive
SOD1 is capable of causing motor neuron degeneration cast
doubt on the hypothesis that oxidative stress caused by aberrant
copper chemistry is a common mechanism in ALS pathology.
Since a SOD1 knock-out mouse does not develop motor neuron
disease [66], and oxidative damage is a well characterised
feature of ALS pathology (see above), it seems plausible that
mutant SOD1 may induce oxidative stress in a mechanism
beyond its own catalytic activity. In support of this, recent
studies showed that expression of mutant SOD1 in a motor
neuronal cell line altered the gene expression profile and caused
a decrease in the cellular anti-oxidant response [81,82]. In the
presence of mutant SOD1, NSC34 motor neuronal cells
underwent transcriptional repression, with genes involved in
anti-oxidant responses representing one of the major groups of
genes to show decreased expression [82]. Several members of
the glutathione S-transferase family, two peroxiredoxins,
glucose-6-phosphate dehydrogenase, an aldo-keto reductase,
and a leukotriene dehydrogenase all showed decreased
expression in the presence of mutant SOD1. The expression
of many of these “programmed cell life” genes involved in the
anti-oxidant response is regulated by the transcription factor
NRF2 [83], which acts through the anti-oxidant response
element (ARE) [84,85]. In the presence of mutant SOD1, the
expression of the transcription factor NRF2 was reduced 3-fold
[82], suggesting that increasing NRF2 signalling may help to
reverse many of these changes. In support of this, pharmaco-
logical activation of the ARE to increase expression of these
genes partly protected against cell death following oxidative
stress induced by serum withdrawal in a cellular model of
SOD1-related ALS [82].
6. Cross-talk with other mechanisms of neurodegeneration
Oxidative stress is just one of several proposed mechanisms
implicated in motor neuron injury in ALS. Other mechanisms
that may contribute to pathogenesis include excitotoxicity,
mitochondrial dysfunction, protein aggregation, cytoskeletal
dysfunction, and involvement of non-neuronal cells, which are
discussed in more detail in other reviews within this issue.
These mechanisms are not mutually exclusive and it seems
probable that they all participate to some extent in disease
progression. Given the large number of genes implicated in
familial ALS [86,87] and the lack of a specific cause of sporadic
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from equilibrium and starts a vicious cycle leading to motor
neuron degeneration. How oxidative stress could be caused by,
and exacerbate other proposed mechanisms is discussed below
(Fig. 5).
6.1. Oxidative stress and excitotoxicity
Excitotoxicity occurs when excessive stimulation of gluta-
mate receptors, the major excitatory neurotransmitter in the
mammalian central nervous system, triggers increased calcium
signalling leading to neuronal injury and death [88,89]. Motor
neurons appear to be particularly vulnerable to excitotoxicity
mediated by AMPA receptors. There is evidence for increased
glutamate signalling in a sub-set of ALS patients [90–93] and in
mutant SOD1-expressing rodent models [64,94,95]. Similarly,
elevated calcium levels have been found in motor nerve
terminals in ALS patients [96] and mutant SOD1 mice [97].
Generation of reactive oxygen species is instrumental in
glutamate-mediated toxicity. Calcium up-take into mitochon-
dria triggered production of ROS [98], and glutamate-induced
degeneration of forebrain neurons was found to be triggered by
up-take of calcium into mitochondria, rather than by the
elevated levels of intracellular free calcium [99]. Similarly,
calcium loading into motor neuron mitochondria, by stimulation
with AMPA, was found to trigger mitochondrial depolarisation
and ROS generation [100].
Reactive oxygen species may in turn be able to trigger
excitotoxicity. Glutamate uptake through both glial and
neuronal glutamate transporters was reduced by exposure to
ROS [101–103]. The peroxidase activity of mutant SOD1 wasFig. 5. Oxidative stress potentially influences other proposed mechanisms of
neurodegeneration in ALS. Excitotoxicity leads to increased intracellular
calcium levels that are buffered by mitochondria leading to increased ROS
production. ROS, in turn, inhibit glutamate uptake through the EAAT2
transporter in glial cells. ROS can also cross the cell membrane and activate
microglia, which respond by releasing cytokines and further ROS. Aberrant
oxidative reactions catalysed by mSOD1 increase production of the highly
reactive peroxynitrite and hydroxyl radical, causing nitration and aggregation of
proteins including mSOD1 itself, and may also inhibit neurofilament assembly
and cytoskeletal transport. Zinc binding to neurofilaments could deplete zinc
binding to mSOD1 and exacerbate aberrant SOD1 chemistry.sufficient to cause oxidation and inactivation of the EAAT2
glutamate transporter in Xenopus oocytes [104] and EAAT2
modified by the lipid peroxidation product 4-hydroxynonenal
has been reported in sporadic ALS patients [105]. Inactivation
of glutamate transporters could lead to persistent high levels of
glutamate in the synapse, triggering excessive activation of
AMPA receptors, increased intracellular calcium levels and
ROS generation.
Excitotoxicity and oxidative stress could combine to form a
feed-forward cycle in which glutamate stimulates increased
influx of calcium into the motor neuron, which is taken up by
mitochondria which in turn results in increasing ROS
generation. The ROS are able to exit the cell and inactivate
glutamate transporters resulting in increased glutamate levels in
the synapse which in turn trigger activation of AMPA receptors
and calcium influx [106]. This vicious cycle could be initiated at
any point in the loop and would ultimately culminate in motor
neuronal death.
6.2. Oxidative stress and mitochondrial dysfunction
There is a substantial body of data that indicate mitochon-
drial dysfunction is a feature of motor neuron degeneration in
ALS [107]. Morphologically abnormal mitochondria have been
observed in motor neurons from ALS patients [96,108,109],
mutant SOD1 transgenic mice [63,110,111] and a motor
neuronal cell line expressing mutant SOD1 [112]. Biochemical
studies have revealed decreased electron transport chain activity
[112–115], reduced mitochondrial membrane potential [116],
altered calcium homeostasis [116,117], and changes to the
mitochondrial proteome [118]. As the major source of reactive
oxygen species (discussed earlier), mitochondria are implicated
in production of oxidative stress, and are also targets of ROS,
with decreased mitochondrial efficiency caused by oxidative
damage being considered a major cause of aging [11–13].
Elevated levels of ROS have been proposed to cause the
increased frequency of mitochondrial DNA mutations in the
motor cortex and spinal cord of ALS patients [115,119], and
could be responsible for the increased translocation of
cytochrome c from mitochondria into the cytoplasm, a trigger
for apoptosis, during disease progression in G93A-SOD1 mice
[120,121].
Although SOD1 is generally considered to be a cytosolic
protein [14], it has recently been established that there is a pool
of enzymatically active SOD1 in the mitochondrial intermem-
brane space [15,20,21]. Mutant SOD1 has also been found
within mitochondria, and such accumulation of mutant SOD1
preceded onset of symptoms in SOD1 transgenic mice [122],
and coincided with increased oxidative damage, decreased
respiratory activity of mitochondria [113] and the appearance of
mitochondrial swelling and vacuolisation [123]. The mecha-
nism by which SOD1 enters the mitochondrion is unknown, but
it seems plausible that it is stimulated by the oxidative damage
that accumulates with age [11–13]. Localisation of mutant
SOD1 to mitochondria was sufficient to cause death of
neuroblastoma cells [124], and high molecular weight aggre-
gates of SOD1 that sequester the anti-apoptotic protein Bcl-2
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death [126].
6.3. Oxidative stress and protein aggregation
Mis-folded mutant proteins that form aggregates are a
common feature of many neurodegenerative diseases including
ALS [65,127–129], although whether they play a role in
disease pathogenesis, are harmless by-products, or represent a
defence mechanism by sequestration of harmful intracellular
proteins is not known [130–132]. Both mutant SOD1
transgenic mice [61,64,65,110,133,134] and cell culture
models [135–137] have also been found to develop protein
aggregates. How SOD1 mutants with defects in the metal
binding region, such as G85R, form aggregates is relatively
straight forward. The structure of SOD1 is stabilized by the
bound metal ions, and SOD1 mutants with reduced metal ion
binding show decreased thermal stability [138] and an
increased tendency to aggregate [139]. Explanation of how
aggregation of “wild type-like” mutants, like A4V and G93A,
occurs is more difficult, although oxidative stress has been
implicated as a contributory factor. Whilst SOD1 mutants with
full metal ion binding and “wild type-like” activity did not
aggregate under control conditions, oxidation of these mutants
led to aggregation [139]. Since aberrant oxidative reactions
catalysed by metal-bound SOD1 mutants caused oxidative
damage to SOD1 itself [48,67,68], it has been proposed that
such oxidative damage could lead to aggregation of mutant
SOD1 [140].
6.4. Oxidative stress and cytoskeletal dysfunction
Neurofilaments constitute a major component of the
intermediate filament network within neuronal cells, and are
responsible for maintaining cell shape and axonal calibre.
Abnormal accumulation of neurofilaments is a pathological
feature of many neurodegenerative disorders including ALS
[141,142] and has also been seen in SOD1 transgenic mice
[61,63,133,143–145]. Neurofilament subunits, classified
according to their molecular weight as light (NF-L), medium
(NF-M) or heavy (NF-H), have been identified as targets for
oxidation by ROS produced by mutant SOD1. Disassembled
NF-L subunits aggregated in response to the peroxidase activity
of SOD1 [146], and axonal transport of neurofilament subunits
was inhibited by the activity of the cyclin-dependent kinase
Cdk5 in response to oxidative stress [147]. Tyrosine residues in
disassembled NF-L subunits were selectively nitrated by SOD1,
and these nitrated NF-L subunits inhibited the assembly of
unmodified neurofilament subunits [148]. Since NF-L is
required for assembly of NF-M and NF-H into neurofilaments
[149], nitration of NF-L could seriously disrupt the maintenance
of the neurofilament network. NF-L has also been shown to
have a sufficiently high affinity for zinc to potentially remove
zinc from both wild-type and mutant SOD1, particularly
mutants with reduced zinc binding [73]. Given that zinc
depleted-SOD1 is more efficient at catalysing peroxynitrite-
mediated tyrosine nitration, a vicious cycle of SOD1-catalysedtyrosine nitration and zinc depletion from SOD1 by NF-L could
potentially develop [73,148].
6.5. Oxidative stress and non-neuronal cells
Evidence is now emerging for involvement of non-
neuronal neighbouring cells in the pathogenesis of ALS.
Activated microglia and astrocytes have been observed in
spinal cord from ALS patients [150] and mutant SOD1
transgenic mice [151,152], and several inflammatory media-
tors have been reported to be up-regulated in the spinal cord
of ALS patients [153,154] and mutant SOD1 mice [155–158].
Although mutant SOD1 was toxic to cultured primary motor
neurons and motor neuronal cell lines [112,135], no motor
deficit or motor neuron degeneration was observed in
transgenic mice with mutant SOD1 expression restricted to
neuronal cells [159,160]. This suggested that non-neuronal
cells play an essential role in disease pathogenesis. However,
expression of mutant SOD1 restricted to astrocytes was also
not sufficient to cause disease [161], indicating that both
neuronal and non-neuronal cells are required for mutant
SOD1-mediated neurodegeneration. In support of this, in
chimeric mice, composed of both normal and mutant SOD1-
expressing cells, normal motor neurons surrounded by non-
neuronal cells expressing mutant SOD1 developed pathology
analogous to ALS, whereas normal non-neuronal cells
increased survival of mutant SOD1-expressing motor neurons
[162]. Reactive oxygen species produced within the motor
neuron can cross the cell membrane [5] and activate
neighbouring astrocytes and microglia [163], which in turn
produce pro-inflammatory cytokines and further reactive
oxygen species, which again spread to neighbouring cells
[164–166]. This mechanism could contribute to the process
by which motor neuron degeneration starts focally but
gradually spreads to contiguous groups of motor neurons
[167].
7. Selective vulnerability of motor neurons
Why motor neurons are selectively vulnerable in ALS,
particularly in mutant SOD1-associated disease, remains an
enigma. The vast majority of neuronal cells are more susceptible
to oxidative stress than other cellular populations because they
are post mitotic, and damage is going to accumulate throughout
life. Motor neurons in particular are highly specialised cells, and
it seems likely that this specialisation renders them vulnerable to
injury [168]. Motor neurons are exceptionally large cells with a
cell body of approximately 50–60 μm and an axon of up to 1 m
long in humans. Maintaining a cell of this size requires a huge
metabolic input, necessary for the production and transport of
cellular components, maintenance of a membrane potential
along the length of the axon, and action potential generation. The
unusually high energy demand of the motor neuron must be met
by a large complement of mitochondria, with the side effect of
increased reactive oxygen species generation. As the vicious
circle of increased ROS production and decreased mitochondrial
efficiency develops with aging [11–13], it may be that the high
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vulnerable to oxidative stress. This may explain why the
proportion of SOD1 that entered mitochondria was greater in
brain than in liver [113]. Mitochondria in motor neurons also
have a greater role in calcium buffering than in other cells, since
motor neurons express lower levels of cytosolic calcium binding
proteins (CaBP, such as parvalbumin and calbindin-D28k) than
other neuronal populations, which act to attenuate calcium
signalling [169–171]. Low expression of CaBP in motor
neurons may force mitochondria to take up more calcium ions
than in other cell types, triggering increased ROS production
[98,100], and may help to explain why addition of glutamate to
cultured motor neurons caused greater increases in ROS than in
other spinal neurons [163]. In support of this, there appears to be
a correlation between low CaBP expression and susceptibility to
ALS [169–172].
This potentially high ROS production by motor neuron
mitochondria may explain why SOD1, which is ubiquitously
expressed, is particularly abundant in motor neurons and is
present in axons and dendrites as well as the cell body [173].
The high levels of SOD1, combined with the probability that
SOD1 has a long half-life in motor neurons (it is transported
anterogradely in the slow component and must have a half-life
of sufficient length to enable it to travel along the length of the
axon [174]), increase the likelihood of potential ROS
production by mutant SOD1 in motor neurons and concomitant
oxidative damage to neurofilaments and SOD1 itself [139]. The
extensive neurofilament network and large amount of plasma
membrane required because of the specific morphological
features of motor neurons provide targets for oxidative
modification.
Oxidative stress is capable of causing considerable damage
to motor neuron populations, and can also influence other
mechanisms implicated in neurodegeneration in motor neuron
disease. Therefore, whether oxidative stress is a primary cause
of disease or a downstream consequence of an earlier toxic
insult becomes almost irrelevant, since it has the ability to
cause massive harm by itself. In the absence of a definitive
cause of neurodegeneration in the majority of ALS cases, it
seems sensible to attempt to target the causes and con-
sequences of oxidative stress for therapeutic intervention.
8. Oxidative stress as a therapeutic target
Oxidative stress has a long history as a therapeutic target
in ALS. The first ‘trial’ of anti-oxidant therapy was reported
in 1940 [175]. This paper relates experience with vitamin E
in combination with wheat germ oils, bile salts, vitamin B
complex and vitamin E containing foods in ALS patients.
This trial does not conform to the current standard of
randomised, double-blind, placebo controlled trials, and few
conclusions can be drawn from this descriptive study.
However, some 65 years later, a Cochrane systematic review
of randomised controlled trials of antioxidant therapy in ALS
failed to find any beneficial effects in the studies which
fulfilled the strict inclusion criteria for the meta-analysis
[176]. The authors concluded that there was no significantevidence to support the benefit of anti-oxidant therapy in
ALS, but that the quality and design of the clinical studies
was generally poor.
When considering the testing of any therapeutic concept, a
negative result does not necessarily falsify a hypothesis and it is
critical to understand the pharmacokinetics and pharmacody-
namics of any agent and to power studies in such a way that they
are likely to detect an effect if it is there. Any in vivo trial is as
much a test of the drug as the therapeutic concept. In the
following section, we have not attempted to be exhaustive, but
cover some examples of common therapeutic strategies which
have so far been pursued for amelioration of oxidative stress in
ALS, and look to possible future directions in this field. In
summary, we contend that data generated so far in human trials
has not sufficiently addressed whether this pathway is relevant
to progression of disease in humans. There is a lack of powerful
anti-oxidants able to access the CNS which are available for
clinical testing. In the industrial R&D setting, there is one
promising candidate in early phase clinical trials (AEOL10150)
and one candidate licensed by Merck but at a very early stage of
development (carboxyfullerenes). In the academic research
arena, a number of potentially exciting ways forward have been
identified, but these must be pursued with rigorous attention to
pre-clinical and clinical trial design, pharmacology and
pharmacokinetics.
9. Completed clinical trials in ALS patients
9.1. Vitamin E
Vitamin E (α-tocopherol) is the most potent naturally
occurring scavenger of ROS and reactive nitrogen species
(RNS) inhibiting radical chain propagation within lipid domains
as it is oxidised to α-tocopheroxyl [177]. Desnuelle et al. carried
out a randomised, placebo controlled double-blind study
comparing vitamin E 500 mg (Toco 500) twice daily versus
placebo, in combination with riluzole in 289 patients with ALS
duration of less than 5 years. There was no effect on the primary
outcome measure (rate of deterioration of function assessed by
the modified Norris scale) and survival was not influenced over
the 12-month trial period. The patients were, however, less
likely to progress to a more severe state of disease as assessed
by the ALS health state scale [178]. More recently, Graf et al.
tested the efficacy of a ‘megadose’ of vitamin E (5000 mg daily)
in a double blind, placebo-controlled, randomised, stratified
parallel-group clinical trial of 18 months duration. One hundred
and sixty patients receiving riluzole were randomised to either
vitamin E or placebo. No effect was detected on the primary
endpoint (time to death, tracheostomy or permanent assisted
ventilation) although the study was powered to detect a 50%
improvement which, as the authors state, may have been too
ambitious. Functional tests showed a marginal trend in favour of
vitamin E and no significant side effects were seen [179].
At face value, these data detract from the hypothesis that
oxidative stress is an important mediator of disease progression
in ALS. There is, however, a hidden assumption that this dose
of vitamin E is sufficient to ameliorate oxidative stress in the
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plasma and ventricular CSF of Parkinson's disease patients
suggests that, despite its lipophilicity, vitamin E does not readily
penetrate the CNS. Five patients with omaya catheters received
oral α-tocopherol, daily over 5 months starting at a dose of
400 IU. The dose was subsequently increased every month to
800, 1600, 3200 and 4000 IU/day. Plasma and ventricular CSF
levels of α-tocopherol were determined at baseline and at the
end of each month. Plasma levels showed a good dose response
with levels increasing from approximately 18.8 μM at baseline
to 110.5 μM at 4000 IU/day. In contrast, there was no increase
above baseline of ventricular CSF levels of α-tocopherol at any
dose. Baseline levels were 0.11 μM and even at supraclinical
doses (4000 IU/day), these levels were statistically unchanged
at 0.16 μM [180]. In a recent paper examining the activity of
several antioxidants in a range of assays, α-tocopherol emerged
as having an IC50 (concentration at which a 50% inhibitory
effect is seen) of 1.5 μM in a glutamate-induced oxidative
neuronal cell death assay, 4.6 μM in a DPPH (2,2-diphenyl-1-
picrylhydrazy) radical scavenging assay and 59 μM in a lipid
peroxidation assay [181]. Based on these data, it is perhaps not
surprising that even very high doses of vitamin E have failed to
show any benefit, not only in ALS but also in other
neurodegenerative diseases [182].
9.2. Selegiline
Selegiline hydrochloride (Eldepryl) is a monoamine oxidase-
B inhibitor with antioxidant properties, which has some
therapeutic benefit in Parkinson's disease. This agent has
been tested over a 6-month period in a double-blind, placebo-
controlled study of 133 patients with classical ALS and
symptoms for less than 3 years. Using rate of change in the
Appel ALS score (AALS) as the primary outcome measure, no
difference was observed between the two groups with a monthly
rate of change of 3.4 points for the selegiline group and 3.5 for
the placebo group. Survival analysis based on worsening of 22
points in the AALS score was also non-significant [183]. It is
known that at the doses used in this trial (5 mg twice daily),
almost 90% of monoamine oxidase-B activity is inhibited in the
human brain [184]. This would suggest that monoamine
oxidase-B plays no role in the pathogenesis of ALS. Whether
the antioxidant functions of selegiline are fully active at these
doses within the CNS is less clear. The proposed anti-oxidant
function of selegiline is related to its ability to act as an inducer
of catalase and superoxide dismutase within the CNS. The data
observed in rodents is conflicting, possibly attributable to age
and species or strain differences and the fact that induction of
these enzymes by selegiline follows a bell shaped dose–
response curve. A recent study looked at the effect of selegiline
dosed subcutaneously (sc) at 2 mg/kg daily on activities of
catalase (CAT), SOD1 and SOD2 (Mn-SOD) in the striatum,
cortex and hippocampus of 8- and 25-week-old rats. At these
doses, which are higher than those used clinically, selegiline
significantly increased CATand SOD2 activities in the striatum,
but not in the cortex and hippocampus, of 25-week-old rats and
had no effect on any enzyme activity in 8 week old rats. Allincreases in expression were less than 2-fold [185]. Although
one would need to examine effects on anti-oxidant systems of
upper and lower motor neurons to assess the potential of this
drug as an anti-oxidant in ALS, it would be difficult to argue
that the clinical trial of selegiline has fully addressed this
potential mechanism. Indeed, the authors of the trial conclude
that two possible reasons for the lack of effect of selegiline on
oxidative mechanisms may be insufficient exposure of spinal
motor neurons to the drug or that its primary mechanism of
action may not be on the oxidative system [183]. In Parkinson's
disease the most likely mechanism of action of the drug is
selective inhibition of MAO-B, resulting in enhanced levels of
phenylethylamine and dopamine but not of serotonin or
noradrenaline in the basal ganglia [186].
9.3. N-acetyl cysteine
N-acetyl cysteine is a precursor of glutathione, a naturally
occurring intracellular anti-oxidant, which is used clinically for
the treatment of paracetamol poisoning and as a mucolytic agent
[187]. A double-blind, randomised, placebo controlled trial of
N-acetyl cysteine has been conducted in 110 patients with ALS
[188]. N-acetylcysteine was self-administered by subcutaneous
infusion at a dose of 50 mg/kg (1 ml/kg) daily for 1 year and a
moderate, but statistically insignificant increase was seen on the
primary end-point of survival. Secondary outcome measures
were designed to assess the rate of disease progression and
included muscle strength testing, myometry and forced vital
capacity. These were also statistically unchanged. The study
was designed to detect a 50% improvement in survival ratio at
1 year with a power of 80% and, as the authors state, the power
to detect smaller effects was limited. In addition when subgroup
analysis was performed there appeared to be opposite effects on
survival in patients with limb and bulbar onset. The authors of
the study state that N-acetyl cysteine is able to reach
cerebrospinal fluid concentrations of up to 3 mg/l, 2–3 h after
a subcutaneous dose of 50 mg/kg although no data is presented
or cited to support this. This is a very high concentration
equivalent to 18.3 μM, and compares favourably with an in
vitro IC50 of 6.5 μM in a glutamate-induced oxidative stress
assay in neurones [181], although other in vitro potency data are
not available as far as we are aware. Although this is a well
conducted trial, the combined limitations of statistical power
and the potentially opposing effects in different subtypes of
MND mean that further trials would be required to definitively
judge the therapeutic potential of this approach.
10. Ongoing clinical trials
10.1. Co-enzyme Q10
Co-enzyme Q10 (CoQ10) is an isoprenoid lipid which is an
essential cofactor for the electron transport chain within
mitochondria and also functions as a lipid soluble anti-oxidant.
Levels of CoQ10 decrease with aging [189]. Distribution studies
of high specific activity radio-labelled CoQ10 and its metabolites
in young rats demonstrated efficient uptake into leukocytes,
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brain. At the subcellular level, the vast majority of CoQ10 was
found in lysosomes presumably because membranes in non-
pathophysiological conditions cannot accommodate more
CoQ10 [190]. In 12-month-old rats, however, feeding with
CoQ10 for 2 months at 200 mg/kg/day in food restored CoQ10
levels to those seen in young rats with a ∼30% increase in non-
perfused cerebral cortex. In cerebral cortex mitochondria, there
were no significant increases after 7 or 30 days feeding, but at
60 days there was a similar enhancement of CoQ10 content
[191]. This study went on to look at the effects of dietary
supplementation with CoQ10 on the SOD1
G93A mouse model of
ALS. In these mice, feeding with CoQ10 at a rate of 200 mg/kg
daily in food prior to onset of symptoms (50 days of age) had a
small effect on survival which was increased from 135 days in
control mice to 141 days in CoQ10 fed mice [191].
Co-enzyme Q10 has been taken forward into small scale
clinical trials in ALS patients. The data are unpublished as far as
we are aware but a brief outline is reported on the ALS
association website (http://www.alsa.org/patient/drug.cfm.). A
pilot study of ‘high dose’ CoQ10 has been completed in 9
patients with ALS and the treatment was well tolerated with no
major adverse events. A second pilot trial with magnetic
resonance spectroscopy (MRS) imaging was conducted but no
further information is available. Enrolment for a larger 9-month
trial of ‘high dose’, ‘very high dose’ and placebo began in
October 2004 and is presumably ongoing. From the animal data
it appears that at best supplementation will restore CoQ10 levels
in mitochondria to levels seen under normal conditions, which
leads to a relatively mild effect in the SOD1G93A preclinical
model of ALS. Whether this effect translates to the clinic
remains to be seen.
10.2. AEOL 10150
AEOL 10150 is a new generation manganese porphyrin that
can catalyse the decomposition of oxidative species by cycling
between Mn (III) and Mn (IV) states. Originally developed as a
SOD mimetic, it also has the capacity to scavenge peroxynitrite.
It has been designed to maximise anti-oxidant properties whilst
minimising possible side-effects [192]. Daily administration of
this compound (2.5 mg/kg) by the intraperitoneal or subcuta-
neous route from symptom onset (∼90 days) in the SOD1G93A
mice led to a significant increase in survival interval, measured
as time from onset to endstage, of 2.5- to 3-fold in several
experiments. Co-administration of creatine and rofecoxib did
not enhance survival beyond that seen in AEOL 10150 treated
mice alone. The overall extension in lifespan was 26%—
impressive for a pharmacological agent dosed at such a late
stage. Analysis of oxidative damage by immunohistochemistry
demonstrated reduced levels of both protein bound nitrotyrosine
and lipid oxidation in spinal cord of drug treated mice 10 days
after initiation of treatment.
Aeolus pharmaceuticals are currently developing AEOL
10150 for use in ALS and have been encouraged by the Food
and Drug Administration (FDA) to apply for fast-track status
which will allow them to conduct a single pivotal phase II/IIItrial (company press release, see http://www.aeoluspharma.
com/). A Phase I escalating single dose study has already been
conducted in ALS patients investigating doses up to 75 mg with
no serious adverse events. A multiple dose study is underway as
of September 2005 investigating doses of 40, 60 and 75 mg
twice daily by the subcutaneous route for 7 days with a single
dose on the final day (data presented at the Rodman and
Renshaw Techvest 7th Annual Healthcare Conference, avail-
able at http://www.wsw.com/webcast/rrshq7/aols/ until Febru-
ary 2006). Indirect analysis of CNS penetrance of the
compound will be performed by analysis of CSF. These doses
are equivalent to ∼2 mg/kg daily which is comparable to the
doses used in the mouse study. The SOD1G93A transgenic
mouse data with AEOL 10150 are probably the strongest
pharmacological evidence for a causative role of oxidative
stress in this model and proper translation of this therapeutic
paradigm to humans will hopefully shed light on its relevance in
ALS.
11. Pre-clinical development
11.1. Fullerenes
Fullerenes, or ‘buckyballs’ as they are better known, are
spherical small molecules which have significant anti-oxidant
capacity. They contain multiple C=C double bonds contain-
ing unpaired electrons which can mop up oxidative species
as well as catalytically dismutating superoxide molecules
[193]. Various derivatives have shown activity in cell culture
model systems of CNS insults [194] and C3, a tris-malonic
acid derivative of buckminsterfullerene (C60), has been
tested in the G93A model of ALS. When delivered by
intraperitoneally implanted osmotic mini-pumps from
73 days of age, C3 dosed mice had an 8-day extension in
survival and scored better on measures of motor performance
[195]. In October 2003 Merck and Co signed a license with
a small biotechnology company called C Sixty to develop
fullerene anti-oxidants in two undisclosed therapeutic areas.
Whether one of these therapeutic areas is ALS is unknown at
present.
11.2. NRF2
A major part of the cells response to oxidative stress is to
increase expression of anti-oxidative defence systems. The
cell achieves this via activation of nuclear factor related
erythroid-2 like-2 protein (NRF2), a transcription factor which
interacts with the anti-oxidant response element (ARE)
enhancer sequence, to promote expression of proteins
involved in glutathione biosynthesis, redox proteins such as
thioredoxin and phase II drug metabolising enzymes [196].
NRF2 is regulated by Kelch-like ECH-associated protein 1
(Keap1) which binds to NRF2, preventing its translocation to
the nucleus. Keap 1 contains a number of cysteine residues
and when these are modified by oxidative stress, NRF2 may
be released allowing it to enter the nucleus and activate ARE
directed transcription [197]. In this way, the NRF2–Keap1
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Other classical signal transduction pathways can also lead to
activation of NRF2 including the major intracellular signalling
cascades involving MAP kinases, such as ERK, PI3 kinases and
protein kinase C (PKC) [196]. A number of small molecules
have been found to activate this pathway and although
structurally diverse they all tend to be nucleophiles which can
react with sulphydryl groups. There has been interest in these
molecules as chemopreventive agents in cancer for several years
[198] and more recently as therapeutic agents in neurodegen-
erative diseases [199]. There are a number of molecules which
can activate this pathway falling into two main categories;
dietary flavonoids and cyclic sulphur containing compounds.
The green tea catechin-(−) epigallocatechin-3-gallate (EGCG) is
a flavonoid which shows neuroprotective effects in a motor
neuronal cell line expressing mutant (G93A) human SOD1. This
cell line was partially protected from H2O2 induced cell death at
concentrations of EGCG greater than 20 μM [200]. This
compound has also been tested in the G93A mouse model of
ALS at doses of 1.5, 2.9 and 5.8 mg/kg, once a day, orally from
60 days of age [201]. At the two higher doses of 2.9 and 5.8 mg/
kg, a significant extension in survival was seen with an increase
in mean survival of 19 and 20 days respectively.
12. Prospects for the future
Despite the lack of success so far in ALS, it is clear that
few potent anti-oxidants able to target the CNS have been
tested in trials powered to detect an effect on survival of less
than 50%. However, there is hope for the future and some of
the promising ways forward are outlined below. Firstly,
identification of more potent and less toxic inducers of the
ARE response outlined above could prove useful agents in
ALS. For example, EGCG is able to induce the Nrf2-ARE
pathway probably because it is itself pro-oxidant [202]
substantially reducing its therapeutic window. This is likely
to be true for other molecules which are known to activate the
ARE. A more refined search for compounds with this activity
but with minimal toxic effects and their subsequent testing in
pre-clinical models of ALS may prove worthwhile. Secondly,
the mitochondrial targeting of compounds with anti-oxidant
properties is also an interesting possibility. As described
earlier, mitochondria are a major source and target of ROS
within motor neurons and it would be of therapeutic benefit
to be able to target anti-oxidants to this compartment. A
lipophilic triphenylphosphonium cation when conjugated to
co-enzyme Q10 [203] or vitamin E [204] was shown to target
these molecules to mitochondria and the conjugates were
several hundredfold more active in mitochondrial oxidative-
stress induced cell death assays [204] than the unconjugated
molecules. Such an approach could be of great benefit in
vivo, particularly if conjugation also enhances CNS pene-
trance of these molecules. Finally, of the approaches already
in the clinic, AEOL10150 is probably the most promising
given the relatively large effects in the G93A mouse model
and its potential to be fast-tracked through the development
process.It is worth noting that despite the cost, time and difficulty
involved in running ALS trials in an academic setting, there are
several examples of well-conducted trials which have given
useful insights. In order to develop effective drugs which target
these pathways in ALS patients and conduct true translational
research, however, a much greater collaborative effort is
required and every stage of the development process needs to
be optimised by those best placed to do so. This is particularly
important in view of the fact that few pharmaceutical/biotech
R&D programmes are active in this small and difficult field. We
believe this review provides a compelling case for targeting
oxidative stress in ALS, an international collaboration of like-
minded academic and industrial scientists, clinicians and
government agencies is now needed to see this exciting project
through to fruition.References
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